A Novel "Molecular Tweezer" Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo

Shubhangi Prabhudesai, Sharmistha Sinha, Aida Attar, Aswani Kotagiri, Arthur G. Fitzmaurice, Ravi Lakshmanan, Magdalena I. Ivanova, Joseph A. Loo, Frank Gerrit Klärner, Thomas Schrader, Mark Stahl, Gal Bitan, Jeff M. Bronstein

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Summary: Aggregation of α-synuclein (α-syn) is implicated as being causative in the pathogenesis of Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. Despite several therapies that improve symptoms in these disorders, none slow disease progression. Recently, a novel "molecular tweezer" (MT) termed CLR01 has been described as a potent inhibitor of assembly and toxicity of multiple amyloidogenic proteins. Here we investigated the ability of CLR01 to inhibit assembly and toxicity of α-syn. In vitro, CLR01 inhibited the assembly of α-syn into β-sheet-rich fibrils and caused disaggregation of pre-formed fibrils, as determined by thioflavin T fluorescence and electron microscopy. α-Syn toxicity was studied in cell cultures and was completely mitigated by CLR01 when α-syn was expressed endogenously or added exogenously. To determine if CLR01 was also protective in vivo, we used a novel zebrafish model of α-syn toxicity (α-syn-ZF), which expresses human, wild-type α-syn in neurons. α-Syn-ZF embryos developed severe deformities due to neuronal apoptosis and most of them died within 48 to 72 h. CLR01 added to the water significantly improved zebrafish phenotype and survival, suppressed α-syn aggregation in neurons, and reduced α-syn-induced apoptosis. α-Syn expression was found to inhibit the ubiquitin proteasome system in α-syn-ZF neurons, resulting in further accumulation of α-syn. Treatment with CLR01 almost completely mitigated the proteasome inhibition. The data suggest that CLR01 is a promising therapeutic agent for the treatment of Parkinson's disease and other synucleinopathies.

Original languageEnglish (US)
Pages (from-to)464-476
Number of pages13
JournalNeurotherapeutics
Volume9
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Synucleins
Zebrafish
Proteasome Endopeptidase Complex
Neurons
Parkinson Disease
Apoptosis
Multiple System Atrophy
Amyloidogenic Proteins
Lewy Body Disease
Aptitude
Ubiquitin
Fluorescence Microscopy
Disease Progression
Electron Microscopy
Embryonic Structures
Cell Culture Techniques
Phenotype
Survival
Water
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Prabhudesai, S., Sinha, S., Attar, A., Kotagiri, A., Fitzmaurice, A. G., Lakshmanan, R., ... Bronstein, J. M. (2012). A Novel "Molecular Tweezer" Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo. Neurotherapeutics, 9(2), 464-476. https://doi.org/10.1007/s13311-012-0105-1
Prabhudesai, Shubhangi ; Sinha, Sharmistha ; Attar, Aida ; Kotagiri, Aswani ; Fitzmaurice, Arthur G. ; Lakshmanan, Ravi ; Ivanova, Magdalena I. ; Loo, Joseph A. ; Klärner, Frank Gerrit ; Schrader, Thomas ; Stahl, Mark ; Bitan, Gal ; Bronstein, Jeff M. / A Novel "Molecular Tweezer" Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo. In: Neurotherapeutics. 2012 ; Vol. 9, No. 2. pp. 464-476.
@article{de00b179ef344aefbd342199a68d44a7,
title = "A Novel {"}Molecular Tweezer{"} Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo",
abstract = "Summary: Aggregation of α-synuclein (α-syn) is implicated as being causative in the pathogenesis of Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. Despite several therapies that improve symptoms in these disorders, none slow disease progression. Recently, a novel {"}molecular tweezer{"} (MT) termed CLR01 has been described as a potent inhibitor of assembly and toxicity of multiple amyloidogenic proteins. Here we investigated the ability of CLR01 to inhibit assembly and toxicity of α-syn. In vitro, CLR01 inhibited the assembly of α-syn into β-sheet-rich fibrils and caused disaggregation of pre-formed fibrils, as determined by thioflavin T fluorescence and electron microscopy. α-Syn toxicity was studied in cell cultures and was completely mitigated by CLR01 when α-syn was expressed endogenously or added exogenously. To determine if CLR01 was also protective in vivo, we used a novel zebrafish model of α-syn toxicity (α-syn-ZF), which expresses human, wild-type α-syn in neurons. α-Syn-ZF embryos developed severe deformities due to neuronal apoptosis and most of them died within 48 to 72 h. CLR01 added to the water significantly improved zebrafish phenotype and survival, suppressed α-syn aggregation in neurons, and reduced α-syn-induced apoptosis. α-Syn expression was found to inhibit the ubiquitin proteasome system in α-syn-ZF neurons, resulting in further accumulation of α-syn. Treatment with CLR01 almost completely mitigated the proteasome inhibition. The data suggest that CLR01 is a promising therapeutic agent for the treatment of Parkinson's disease and other synucleinopathies.",
author = "Shubhangi Prabhudesai and Sharmistha Sinha and Aida Attar and Aswani Kotagiri and Fitzmaurice, {Arthur G.} and Ravi Lakshmanan and Ivanova, {Magdalena I.} and Loo, {Joseph A.} and Kl{\"a}rner, {Frank Gerrit} and Thomas Schrader and Mark Stahl and Gal Bitan and Bronstein, {Jeff M.}",
year = "2012",
month = "4",
doi = "10.1007/s13311-012-0105-1",
language = "English (US)",
volume = "9",
pages = "464--476",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "2",

}

Prabhudesai, S, Sinha, S, Attar, A, Kotagiri, A, Fitzmaurice, AG, Lakshmanan, R, Ivanova, MI, Loo, JA, Klärner, FG, Schrader, T, Stahl, M, Bitan, G & Bronstein, JM 2012, 'A Novel "Molecular Tweezer" Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo', Neurotherapeutics, vol. 9, no. 2, pp. 464-476. https://doi.org/10.1007/s13311-012-0105-1

A Novel "Molecular Tweezer" Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo. / Prabhudesai, Shubhangi; Sinha, Sharmistha; Attar, Aida; Kotagiri, Aswani; Fitzmaurice, Arthur G.; Lakshmanan, Ravi; Ivanova, Magdalena I.; Loo, Joseph A.; Klärner, Frank Gerrit; Schrader, Thomas; Stahl, Mark; Bitan, Gal; Bronstein, Jeff M.

In: Neurotherapeutics, Vol. 9, No. 2, 04.2012, p. 464-476.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Novel "Molecular Tweezer" Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo

AU - Prabhudesai, Shubhangi

AU - Sinha, Sharmistha

AU - Attar, Aida

AU - Kotagiri, Aswani

AU - Fitzmaurice, Arthur G.

AU - Lakshmanan, Ravi

AU - Ivanova, Magdalena I.

AU - Loo, Joseph A.

AU - Klärner, Frank Gerrit

AU - Schrader, Thomas

AU - Stahl, Mark

AU - Bitan, Gal

AU - Bronstein, Jeff M.

PY - 2012/4

Y1 - 2012/4

N2 - Summary: Aggregation of α-synuclein (α-syn) is implicated as being causative in the pathogenesis of Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. Despite several therapies that improve symptoms in these disorders, none slow disease progression. Recently, a novel "molecular tweezer" (MT) termed CLR01 has been described as a potent inhibitor of assembly and toxicity of multiple amyloidogenic proteins. Here we investigated the ability of CLR01 to inhibit assembly and toxicity of α-syn. In vitro, CLR01 inhibited the assembly of α-syn into β-sheet-rich fibrils and caused disaggregation of pre-formed fibrils, as determined by thioflavin T fluorescence and electron microscopy. α-Syn toxicity was studied in cell cultures and was completely mitigated by CLR01 when α-syn was expressed endogenously or added exogenously. To determine if CLR01 was also protective in vivo, we used a novel zebrafish model of α-syn toxicity (α-syn-ZF), which expresses human, wild-type α-syn in neurons. α-Syn-ZF embryos developed severe deformities due to neuronal apoptosis and most of them died within 48 to 72 h. CLR01 added to the water significantly improved zebrafish phenotype and survival, suppressed α-syn aggregation in neurons, and reduced α-syn-induced apoptosis. α-Syn expression was found to inhibit the ubiquitin proteasome system in α-syn-ZF neurons, resulting in further accumulation of α-syn. Treatment with CLR01 almost completely mitigated the proteasome inhibition. The data suggest that CLR01 is a promising therapeutic agent for the treatment of Parkinson's disease and other synucleinopathies.

AB - Summary: Aggregation of α-synuclein (α-syn) is implicated as being causative in the pathogenesis of Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. Despite several therapies that improve symptoms in these disorders, none slow disease progression. Recently, a novel "molecular tweezer" (MT) termed CLR01 has been described as a potent inhibitor of assembly and toxicity of multiple amyloidogenic proteins. Here we investigated the ability of CLR01 to inhibit assembly and toxicity of α-syn. In vitro, CLR01 inhibited the assembly of α-syn into β-sheet-rich fibrils and caused disaggregation of pre-formed fibrils, as determined by thioflavin T fluorescence and electron microscopy. α-Syn toxicity was studied in cell cultures and was completely mitigated by CLR01 when α-syn was expressed endogenously or added exogenously. To determine if CLR01 was also protective in vivo, we used a novel zebrafish model of α-syn toxicity (α-syn-ZF), which expresses human, wild-type α-syn in neurons. α-Syn-ZF embryos developed severe deformities due to neuronal apoptosis and most of them died within 48 to 72 h. CLR01 added to the water significantly improved zebrafish phenotype and survival, suppressed α-syn aggregation in neurons, and reduced α-syn-induced apoptosis. α-Syn expression was found to inhibit the ubiquitin proteasome system in α-syn-ZF neurons, resulting in further accumulation of α-syn. Treatment with CLR01 almost completely mitigated the proteasome inhibition. The data suggest that CLR01 is a promising therapeutic agent for the treatment of Parkinson's disease and other synucleinopathies.

UR - http://www.scopus.com/inward/record.url?scp=84859708060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859708060&partnerID=8YFLogxK

U2 - 10.1007/s13311-012-0105-1

DO - 10.1007/s13311-012-0105-1

M3 - Article

C2 - 22373667

AN - SCOPUS:84859708060

VL - 9

SP - 464

EP - 476

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 2

ER -

Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R et al. A Novel "Molecular Tweezer" Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo. Neurotherapeutics. 2012 Apr;9(2):464-476. https://doi.org/10.1007/s13311-012-0105-1